Vykat XR News

Latest Articles

• Neurocrine Biosciences Enters Metabolic Market with $2.9 Billion Cash Acquisition of Soleno Therapeutics

  Published: Apr 7, 2026

  Section: Markets

  Neurocrine Biosciences has agreed to acquire rare-disease specialist Soleno Therapeutics for $2.9 billion to secure Vykat XR, the first FDA-approved treatment for Prader-Willi synd...